[Calmette-Guerin (BCG) vaccination].
The reappearance of tuberculosis in France, in Europe and throughout the world has rekindled interest not only in curative treatment of the disease but also in its prevention. Since its appearance in 1921, the BCG vaccine has been the subject of debate; however, recent studies have fully demonstrated its interest, particularly in countries where tuberculosis is most endemic. The technical aspects of the treatment have changed little and are essentially based on intrademic administration, but the impact of BCG, especially for individual protection, are discussed. Its role in protection of the general population and in prevention of tuberculosis requires careful analysis. Study of iatrogenic effects of the vaccine shows that its side effects are minor when recommendations for use are followed. With the development of molecular biology techniques and mycobacteria genetics, the future use of the BCG vaccine seems promising.
Bonnaud
F
F
Comité national contre les maladies respiratoires et la tuberculose (CNMRT), Paris.
D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology; D002648:Child; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000628:therapy; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D014376:Tuberculosis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*
D001500:BCG Vaccine